About Edixomed
Edixomed is a company based in Edinburgh (United Kingdom) founded in 2009 by Chris Wood. Edixomed has raised $2.2 million across 3 funding rounds from investors including Scottish Enterprise, Medical Research Council and Alida Capital International. The company has 5 employees as of July 31, 2020. Edixomed operates in a competitive market with competitors including Imbed Biosciences, Adocia, Cresilon, QBiotics and MediWound, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 5 as on 31 Jul, 2020
- Founders Chris Wood
-
Sectors
TechnologyHealthcare Aerospace, Defense & Maritime
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Edixomed Limited
- Date of Incorporation 28 Jul, 2009
- Jurisdiction EDINBURGH, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
-$2.12 M (USD)0as on Dec 31, 2020
-
EBITDA
Not available
-
Total Equity Funding
$2.2 M (USD)
in 3 rounds
-
Latest Funding Round
$386.42 K (USD), Grant
May 15, 2017
-
Investors
Scottish Enterprise
& 3 more
-
Employee Count
5
as on Jul 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Edixomed
Edixomed has successfully raised a total of $2.2M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $386.42 thousand completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Edixomed
Edixomed has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Scottish Enterprise, Medical Research Council and Alida Capital International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Business development and leadership training programs are offered to companies.
|
Locked | Locked | Locked | |
|
Medical research is conducted to advance human health improvements.
|
Locked | Locked | Locked |
Investor details for Edixomed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Edixomed
Investment portfolio details for Edixomed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Edixomed
Detailed financials for Edixomed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Edixomed Comparisons
Peer comparison for Edixomed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Edixomed
Edixomed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Imbed Biosciences, Adocia, Cresilon, QBiotics and MediWound, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanotech-based wound care products are developed and provided.
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of hemostatic products for wound care
|
|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
Detailed competitors of Edixomed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Edixomed
Complete news archive for Edixomed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Edixomed
Edixomed was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Edixomed is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Syd Hanna is the current CEO of Edixomed.
Edixomed is a funded company, having raised a total of $2.2M across 3 funding rounds to date.
As of Jul 31, 2020, the latest employee count at Edixomed is 5.
Edixomed was founded in 2009 in Edinburgh, United Kingdom, within the medical devices sector. Nitric oxide-releasing wound dressings are developed and produced to treat chronic diabetic ulcers. Therapeutic solutions are formulated to promote tissue repair, enhance blood flow, and control infections in wounds. Processes encompass formulation, testing, and clinical preparation, with quality protocols applied to ensure safety, consistency, and effective delivery of active agents.
Edixomed's top competitors include Imbed Biosciences, Adocia and Ilya Pharma.
Edixomed has 4 investors. Key investors include Scottish Enterprise, Medical Research Council, Alida Capital International, and SBRI Healthcare.